ChiCTR-TRC-13004069 版本V1.0 版本创建时间2016/06/19 21:46:50 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR-TRC-13004069 

最近更新日期:

Date of Last Refreshed on:

2015-05-05 12:44:32 

注册时间:

Date of Registration:

2013-04-10 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

苦丁香通气栓III期临床研究

Public title:

Phase III Clinical Trial of Kudingxiang Tong Qi Suppository

注册题目简写:

苦丁香通气栓

English Acronym:

TQS

研究课题的正式科学名称:

苦丁香通气栓治疗腹部手术后肠麻痹有效性及安全性的随机、双盲、安慰剂平行对照、多中心临床试验

Scientific title:

A randomized, double blinded, placebo controlled, parallel grouped, multi-centre clinical study on safety and efficacy of TQS for restoring gastrointestinal function after abdominal surgery

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

2009L01190

申请注册联系人:

谢忱 

研究负责人:

谢忱 

Applicant:

Chen Xie 

Study leader:

Chen Xie 

申请注册联系人电话:

Applicant telephone:

+86 13501261306

研究负责人电话:

Study leader's
telephone:

+86 13501261306

申请注册联系人传真 :

Applicant Fax:

+86-10-80729874

研究负责人传真:

Study leader's fax:

+86-10-80729874

申请注册联系人电子邮件:

Applicant E-mail:

cxie@botaniccentury.com

研究负责人电子邮件:

Study leader's E-mail:

cxie@botaniccentury.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

www.snykpharma.com

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

www.snykpharma.com

申请注册联系人通讯地址:

北京市海淀区开拓路5号A-401

研究负责人通讯地址:

北京市海淀区开拓路5号A-401

Applicant address:

A-401, 5, KaiTuo Road, Haidian District, Beijing, China

Study leader's address:

A-401, 5 Kai Tuo Road, Haidian District, Beijing, China

申请注册联系人邮政编码:

Applicant postcode:

100085

研究负责人邮政编码:

Study leader's postcode:

100085

申请人所在单位:

北京神农益康医药技术有限公司

Applicant's institution:

Beijing SNYK Pharmaceutical Ltd

研究负责人所在单位:

Affiliation of the Leader:

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

E2012]伦审药临字第(28)号

伦理委员会批件附件:

Approved file of Ethical Committee:

批准本研究的伦理委员会名称:

北京大学人民医院医学伦理委员会

Name of the ethic committee:

The Medical Ethics Committee of Renmin Hospital, Bejing University

伦理委员会批准日期:

Date of approved by ethic committee:

2011-09-05 00:00:00

伦理委员会联系人:

Contact Name of the ethic committee:

伦理委员会联系地址:

Contact Address of the ethic committee:

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

北京大学人民医院

Primary sponsor:

Renmin Hospital of Beijing University

研究实施负责(组长)单位地址:

北京市西城区阜成门内大街133号

Primary sponsor's address:

133 FuChengMenNei Street, XiCheng District, Beijing, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

经费或物资来源:

北京神农益康医药技术有限公司

Source(s) of funding:

Funded by SNYK Pharmaceutical Ltd

研究疾病:

手术后肠麻痹  

Target disease:

Post Operative Illes

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

III期临床试验 

Study phase:

3

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

在Ⅱb期基础上,确证苦丁香通气栓治疗腹部手术后肠麻痹的有效性及安全性,为注册审查提供依据。  

Objectives of Study:

Based on Phase IIb clinical trial, to further investigate the efficacy and safety of TQS on restoring gastrointestinal function after abdominal surgery, and to provide the evidence for New drug Application.

药物成份或治疗方案详述:

苦丁香,槟榔 

Description for medicine or protocol of treatment in detail:

Muskmelon-Base and Arecae semen Extract 

纳入标准:

⑴ 开腹胃肠道手术患者;
⑵ 手术麻醉方式为全麻,术后采用静脉镇痛的患者;
⑶ 年龄在18~75岁,性别不限;
⑷ 自愿签署知情同意书者。

Inclusion criteria

(1)Open abdominal gastrointestinal surgery;(2)Surgery with general anesthesia, and intravenous analgesia after surgey;(3)Aged 18~75;(4)Volantarily to sign the informed consent file.

排除标准:

⑴ 行直肠吻合术的患者;或肠道皮肤造瘘者;
⑵ 恶性肿瘤腹腔广泛转移或广泛粘连;或急性肠梗阻患者;
⑶ 酸中毒、高渗性非酮症昏迷,严重脱水、严重电解质紊乱等患者;
⑷ 合并严重心脑血管疾病者及造血系统严重原发疾病者;
⑸ 1型糖尿病或2型糖尿病血糖控制不满意,空腹血糖>8mmol/L的患者;
⑹ 肝功能(ALT)>正常值上限1.5倍者,或血肌酐(Cr)高于正常值上限者;
⑺ 过度肥胖(BMI>30),严重营养不良(BMI<15)者;
⑻ 过敏体质或对多种药物(两种以上)有过敏史者;
⑼ 妊娠、哺乳期妇女,近期有生育计划者;
⑽ 4周内参加过其它药物临床试验者;
⑾ 研究者认为不适宜参加本项临床试验者,如手术时间过长,术中有重大并发症,术后12小时内呼吸循环不稳定者等。

Exclusion criteria:

(1)Patients under rectal anastomosis or intestinal fistulation;
(2)Patients with extensive malignant tumor abdominal cavity metastasis or adhesion; or acute intestinal obstruction;
(3)Patients with acidosis/HONKC/severe dehydration/severe electrolyte disorder;
(4)Patients complicated with severe cardiac-cerebral vascular disease or severe primary hematopoietic system disease;
(5)Patients of Type 1 or 2 diabetic with fasting blood-glucose>8mmol/L;
(6)Patients with ALT>1.5 times upper normal limit or Cr> upper normal limit;
(7)BMI>30 or BMI<15;
(8)Patients with allergic constitution or allergic to drugs(>2 drugs);
(9)Pregnant or lactating women,or who has short term plan for pregnancy;
(10)Patients participated in any clinical trials in the past 4 weeks.
(11)Patients, decided by the investigator, not suitable for the trial, such as with excessively long operation time, severe complication, unstable respiration and circulation system 12 hours after surgery, ect.

研究实施时间:

Study execute time:

From 2012-09-05 00:00:00 To 2014-06-30 00:00:00  

征募观察对象时间:

Recruiting time:

From 2012-09-05 00:00:00 To 2014-06-16 00:00:00

干预措施:

Interventions:

组别:

试验组

样本量:

330

Group:

QWE

Sample size:

干预措施:

术后12小时24小时肛门给药一次(苦丁香通气栓)

干预措施代码:

Intervention:

QQE

Intervention code:

组别:

安慰剂

样本量:

110

Group:

QWE

Sample size:

干预措施:

术后12小时24小时肛门给药一次(苦丁香通气栓模拟剂)

干预措施代码:

Intervention:

QQE placebo

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

北京 

市(区县):

 

Country:

China

Province:

Beijing

City:

单位(医院):

北京大学人民医院 

单位级别:

三级甲等 

Institution
hospital:

Peking University People's Hospital

Level of the institution:

Tertiary A hospital

国家:

中国

省(直辖市):

北京 

市(区县):

 

Country:

China

Province:

Beijing

City:

单位(医院):

首都医科大学附属北京友谊医院 

单位级别:

三甲 

Institution
hospital:

Beijing Friendship Hospital of the Capital Medical University

Level of the institution:

Tertiary A hospital

国家:

中国

省(直辖市):

北京 

市(区县):

 

Country:

China

Province:

Beijing

City:

单位(医院):

北京大学首钢医院 

单位级别:

三甲医院 

Institution
hospital:

Peking University Shougang Hospital

Level of the institution:

Tertiary A hospital

国家:

中国

省(直辖市):

北京 

市(区县):

 

Country:

China

Province:

Beijing

City:

单位(医院):

中国人民解放军成都军区总医院 

单位级别:

三甲医院 

Institution
hospital:

General Hospital of Chengdu Military Region of PLA

Level of the institution:

Tertiary A hospital

国家:

中国

省(直辖市):

武汉 

市(区县):

 

Country:

China

Province:

wuhan

City:

单位(医院):

华中科技大学同济医学院附属协和医院 

单位级别:

三甲 

Institution
hospital:

Union Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology.

Level of the institution:

Tertiary A hospital

国家:

中国

省(直辖市):

重庆 

市(区县):

 

Country:

China

Province:

chongqing

City:

单位(医院):

重庆医科大学附属第二医院 

单位级别:

三甲 

Institution
hospital:

The second affilat ed hospital of chongoinc medical university

Level of the institution:

Tertiary A hospital

国家:

中国

省(直辖市):

上海 

市(区县):

 

Country:

China

Province:

shanghai

City:

单位(医院):

上海中医药大学附属普陀医院 

单位级别:

三甲医院 

Institution
hospital:

Putuo District Center Hospital

Level of the institution:

Tertiary A hospital

国家:

中国

省(直辖市):

江苏 

市(区县):

 

Country:

China

Province:

jiangsu

City:

单位(医院):

南京市第一医院 

单位级别:

三甲 

Institution
hospital:

Nan Jing Fifst Hospital

Level of the institution:

Tertiary A hospital

国家:

中国

省(直辖市):

山东 

市(区县):

 

Country:

China

Province:

shandong

City:

单位(医院):

青岛大学医学院附属医院 

单位级别:

三甲医院 

Institution
hospital:

The affiliated hospital of medical college QingDao university

Level of the institution:

Tertiary A hospital

测量指标:

Outcomes:

指标中文名:

手术后首次排气时间

指标类型:

主要指标

Outcome:

Time to first passing flatus: time to first passing flatus after surgery

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

手术后首次排便时间

指标类型:

主要指标

Outcome:

Time to first passage of stool: time to first passage of stool after surgery

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

手术后首次肠鸣音出现时间(医生听诊

指标类型:

次要指标

Outcome:

The time to the first bowel sounds by doctor auscultation

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

手术后进食固体食物耐受时间

指标类型:

次要指标

Outcome:

Time to first tolerent of solid food

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

理论出院时间

指标类型:

次要指标

Outcome:

Theoretical discharge time

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

体格检查

指标类型:

副作用指标

Outcome:

Physical examination

Type:

Adverse events

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

理化检查

指标类型:

副作用指标

Outcome:

Laboratory examination

Type:

Adverse events

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

不良事件报告

指标类型:

副作用指标

Outcome:

Adverse event report

Type:

Adverse events

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

标本中文名:

尿液

组织:

Sample Name:

urine

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

正在进行

Recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 75 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

采用分层区组随机化方法。由统计师按中心进行分层,选取合适段长。借助SAS统计软件,给定种子数,产生440例(试验组和安慰剂组)受试者所接受处理的随机安排,列出流水号为001~440所对应的治疗分配(即

Randomization Procedure (please state who generates the random number sequence and by what method):

A stratified blocked randomisation method was applied. Stratification was based on centres and prope

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

双盲法

Blinding:

Double-blind

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

数据与安全监察委员会:

Data and Safety Monitoring Committee:

注册人:

Name of Registration:

 2013-12-31 00:00:00